Prevalence and incidence of dengue virus and antibody placental transfer during late pregnancy in central Brazil

BMC Infectious Diseases

Celina MT Martelli²  Cynthia Braga¹  João Bosco Siqueira Júnior³  Luiz A Pereira⁵  Anna Carolina M Oliveira⁴  Lucimeire A Silveira³  Valéria CR Féres⁴  Angela FLT Argolo³ 

[1] Fundação Oswaldo Cruz, Centro de Pesquisas Aggeu Magalhães. Av Moraes Rego, s/n, Cidade Universitária, Recife, PE, 50000-230, Brazil;Universidade Federal de Pernambuco, Av. Prof. Moraes Rego, s/n - Cidade Universitária, Recife, PE, 50670-420, Brazil;Universidade Federal de Goiás, Instituto de Patologia Tropical e Saúde Publica, Departamento de Saúde Coletiva. Rua Delenda Rezende de Mello, S/N - Sala 405, Setor Universitário, Goiania, GO, 74605-050, Brazil;Universidade Federal de Goiás, Faculdade de Farmácia, Av. Universitária esquina com 1ª Avenida, s/n, St. Universitário, Goiânia, GO, 74.605-220, Brazil;Secretaria de Estado da Saúde de Goiás, Laboratório de Saúde Pública (LACEN-GO), Av. Contorno, 3.556, Jd. Bela Vista, Goiânia, GO, 74.853-120, Brazil

关键词: Vertical transmission;    Neonate;    Pregnant;    Incidence;    Prevalence;    Dengue;   

Others  :  1148063
DOI  :  10.1186/1471-2334-13-254

 received in 2012-12-19, accepted in 2013-05-24,  发布年份 2013

【 摘 要 】

Background

Maternal dengue antibodies are considered to play a significant role in dengue pathogenesis among infants. Determining the transplacental specific antibody transfer is invaluable for establishing the optimal vaccination age among infants in endemic regions.

Methods

We conducted a cross-sectional study among pairs of maternal and corresponding umbilical cord blood samples in public hospitals. The prevalence and incidence of dengue infection were determined in 505 pairs of pregnant women and neonates during a large outbreak (2009–2010) in central Brazil. The women were interviewed at late pregnancy to assess current or past symptoms of dengue. All parturients and their neonates were screened using Dengue IgG Indirect ELISA (Panbio) to assess previous dengue exposure. A semi-quantitative measurement of the IgG antibody expressed by the index ratio was calculated using optical density (OD) values according to the manufacturer’s instructions. The studied population of parturients and their offspring was also screened for recent dengue infection by the Dengue IgM-capture ELISA (Panbio). Those participants with history of fever and two or more symptoms of dengue at least 10 days before the delivery were also tested for the dengue NS1 antigen using the Dengue Early ELISA (Panbio) and RT-PCR.

Results

The mean maternal age was 25.8 (SD = 6.4), and 83.6% of deliveries were between 37 and 41 weeks. Approximately half of the 505 women and neonates were IgG-seropositive, yielding 99.3% co-positive mother-child frequency of antibody transfer (Kappa = 0.96). The incidence of dengue infection was 2.8% (95% CI 1.4–4.4%) among the women considering 14 IgM-positive results and one DENV2 detected by RT-PCR. The dengue NS1 antigen was undetectable in the matched pairs.

Conclusion

This study provides critical data on the prevalence of transplacental transferred maternal-infant anti-dengue antibodies and incidence of infection. The design of future vaccine trials should consider diverse regional epidemiological scenarios.

【 授权许可】

   
2013 Argolo et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

【 参考文献 】

• [1]World Health Organization: Dengue: guidelines for diagnosis, treatment, prevention and control. Geneva, Switzerland: World Health Organization; 2009.
• [2]Gubler DJ: Epidemic dengue/dengue hemorrhagic fever as a public health, social and economic problem in the 21st century. Trends Microbiol 2002, 10(2):100-103.
• [3]Harris E, Videa E, Perez L, Sandoval E, Tellez Y, Perez ML, Cuadra R, Rocha J, Idiaquez W, Alonso RE: Clinical, epidemiologic, and virologic features of dengue in the 1998 epidemic in Nicaragua. Am J Trop Med Hyg 2000, 63(1–2):5-11.
• [4]Russell PK, Udomsakdi S, Halstead SB: Antibody response in dengue and dengue hemorrhagic fever. Jpn J Med Sci Biol 1967, 20(Suppl):103-108.
• [5]Ooi EE, Goh KT, Gubler DJ: Dengue prevention and 35 years of vector control in Singapore. Emerg Infect Dis 2006, 12(6):887-893.
• [6]Siqueira JB Jr, Martelli CM, Coelho GE, Simplicio AC, Hatch DL: Dengue and dengue hemorrhagic fever, Brazil, 1981–2002. Emerg Infect Dis 2005, 11(1):48-53.
• [7]Nogueira RM, Miagostovich MP, Lampe E, Souza RW, Zagne SM, Schatzmayr HG: Dengue epidemic in the stage of Rio de Janeiro, Brazil, 1990–1: co-circulation of dengue 1 and dengue 2 serotypes. Epidemiol Infect 1993, 111(1):163-170.
• [8]Brazilian Minister of Health: Isolation of DENV-4 in Roraima/AM. [http://portal.saude.gov.br/portal/arquivos/pdf/nt_denv_4reveduardo2.pdf webcite]
• [9]Teixeira MG, Costa MC, Coelho G, Barreto ML: Recent shift in age pattern of dengue hemorrhagic fever. Brazil. Emerg Infect Dis 2008, 14(10):1663.
• [10]Ferguson NM, Donnelly CA, Anderson RM: Transmission dynamics and epidemiology of dengue: insights from age-stratified sero-prevalence surveys. Philos Trans R Soc Lond B Biol Sci 1999, 354(1384):757-768.
• [11]Halstead SB: Antibodies determine virulence in dengue. Ann N Y Acad Sci 2009, 1171(Suppl 1):E48-E56.
• [12]Pouliot SH, Xiong X, Harville E, Paz-Soldan V, Tomashek KM, Breart G, Buekens P: Maternal dengue and pregnancy outcomes: a systematic review. Obstet Gynecol Surv 2010, 65(2):107-118.
• [13]Jain A, Chaturvedi UC: Dengue in infants: an overview. FEMS Immunol Med Microbiol 2010, 59(2):119-130.
• [14]Kliks SC, Nimmanitya S, Nisalak A, Burke DS: Evidence that maternal dengue antibodies are important in the development of dengue hemorrhagic fever in infants. Am J Trop Med Hyg 1988, 38(2):411-419.
• [15]Halstead SB, Udomsakdi S, Simasthien P, Singharaj P, Sukhavachana P, Nisalak A: Observations related to pathogenesis of dengue hemorrhagic fever. I. Experience with classification of dengue viruses. Yale J Biol Med 1970, 42(5):261-275.
• [16]Endy TP, Nisalak A, Chunsuttitwat S, Vaughn DW, Green S, Ennis FA, Rothman AL, Libraty DH: Relationship of preexisting dengue virus (DV) neutralizing antibody levels to viremia and severity of disease in a prospective cohort study of DV infection in Thailand. J Infect Dis 2004, 189(6):990-1000.
• [17]Laoprasopwattana K, Libraty DH, Endy TP, Nisalak A, Chunsuttiwat S, Vaughn DW, Reed G, Ennis FA, Rothman AL, Green S: Dengue Virus (DV) enhancing antibody activity in preillness plasma does not predict subsequent disease severity or viremia in secondary DV infection. J Infect Dis 2005, 192(3):510-519.
• [18]The Brazilian Institute of Geography and Statistics (IBGE): Cities@. [http://www.ibge.gov.br/cidadesat/link.php?codmun=520870 webcite]
• [19]Feres VC, Martelli CM, Turchi MD, Junior JB, Nogueira RM, Rocha BA, Silva LF, de Jesus Silva MM, de Paula Cardoso Dda D: Laboratory surveillance of dengue virus in Central Brazil, 1994–2003. J Clin Virol 2006, 37(3):179-183.
• [20]Brazilian Ministry of Health: Health Brazil 2010: Health analysis and selected evidences on impact of health surveillance actions. Brasilia Ministry of Health, Secretariat of Health Surveillance 2010, 7, 156-171.
• [21]Brazilian Minister of Health: Portal da Saude. Sistema de Informação de Agravos de Notificação. [http://dtr2004.saude.gov.br/sinanweb/tabnet/dh?sinannet/dengue/bases/denguebrnet.def webcite]
• [22]Kuno G, Gomez I, Gubler DJ: Detecting artificial anti-dengue IgM immune complexes using an enzyme-linked immunosorbent assay. Am J Trop Med Hyg 1987, 36(1):153-159.
• [23]da Rosa AP T, Travassos Da Rosa ES, Travassos Da Rosa JFS, Dégallier N, Vasconcelos PF, Rodrigues SG: Os arbovírus no Brasil: generalidades, métodos e técnicas de estudo 2. Belém-PA: Instituto Evandro Chagas. Fundação Nacional de Saúde; 1994:23.
• [24]Lanciotti RS, Calisher CH, Gubler DJ, Chang GJ, Vorndam AV: Rapid detection and typing of dengue viruses from clinical samples by using reverse transcriptase-polymerase chain reaction. J Clin Microbiol 1992, 30(3):545-551.
• [25]Pengsaa K, Luxemburger C, Sabchareon A, Limkittikul K, Yoksan S, Chambonneau L, Chaovarind U, Sirivichayakul C, Lapphra K, Chanthavanich P: Dengue virus infections in the first 2 years of life and the kinetics of transplacentally transferred dengue neutralizing antibodies in thai children. J Infect Dis 2006, 194(11):1570-1576.
• [26]Simmons CP, Chau TN, Thuy TT, Tuan NM, Hoang DM, Thien NT, le Lien B, Quy NT, Hieu NT, Hien TT: Maternal antibody and viral factors in the pathogenesis of dengue virus in infants. J Infect Dis 2007, 196(3):416-424.
• [27]Watanaveeradej V, Endy TP, Samakoses R, Kerdpanich A, Simasathien S, Polprasert N, Aree C, Vaughn DW, Ho C, Nisalak A: Transplacentally transferred maternal-infant antibodies to dengue virus. Am J Trop Med Hyg 2003, 69(2):123-128.
• [28]Palmeira P, Quinello C, Silveira-Lessa AL, Zago CA, Carneiro-Sampaio M: IgG placental transfer in healthy and pathological pregnancies. Clin Dev Immunol 2012, 2012:985646.
• [29]Tan PC, Rajasingam G, Devi S, Omar SZ: Dengue infection in pregnancy: prevalence, vertical transmission, and pregnancy outcome. Obstet Gynecol 2008, 111(5):1111-1117.
• [30]Braga C, Luna CF, Martelli CM, de Souza WV, Cordeiro MT, Alexander N, de Albuquerque MF, Junior JC, Marques ET: Seroprevalence and risk factors for dengue infection in socio-economically distinct areas of Recife, Brazil. Acta Trop 2009, 113(3):234-240.
• [31]Siqueira JB, Martelli CM, Maciel IJ, Oliveira RM, Ribeiro MG, Amorim FP, Moreira BC, Cardoso DD, Souza WV, Andrade AL: Household survey of dengue infection in central Brazil: spatial point pattern analysis and risk factors assessment. Am J Trop Med Hyg 2004, 71(5):646-651.
• [32]Siqueira-Junior JB, Maciel IJ, Barcellos C, Souza WV, Carvalho MS, Nascimento NE, Oliveira RM, Morais-Neto O, Martelli CM: Spatial point analysis based on dengue surveys at household level in central Brazil. BMC Public Health 2008, 8:361. BioMed Central Full Text
• [33]Halstead SB: Dengue in the Americas and Southeast Asia: do they differ? Rev Panam Salud Publica 2006, 20(6):407-415.
• [34]Blacksell SD, Jarman RG, Gibbons RV, Tanganuchitcharnchai A, Mammen MP Jr, Nisalak A, Kalayanarooj S, Bailey MS, Premaratna R, de Silva HJ: Comparison of seven commercial antigen and antibody enzyme-linked immunosorbent assays for detection of acute dengue infection. Clin Vaccine Immunol 2012, 19(5):804-810.
• [35]Cordeiro MT: Laboratory diagnosis for dengue. Rev Inst Med Trop Sao Paulo 2012, 54(Suppl 18):10-12.
• [36]Hunsperger EA, Yoksan S, Buchy P, Nguyen VC, Sekaran SD, Enria DA, Pelegrino JL, Vazquez S, Artsob H, Drebot M: Evaluation of commercially available anti-dengue virus immunoglobulin M tests. Emerg Infect Dis 2009, 15(3):436-440.
• [37]Brambell FW, Hemmings WA, Oakley CL, Porter RR: The relative transmission of the fractions of papain hydrolyzed homologous gamma-globulin from the uterine cavity to the foetal circulation in the rabbit. Proc R Soc Lond B Biol Sci 1960, 151:478-482.
• [38]Wahala WMPB, Silva AM: The human antibody response to dengue virus infection. Viruses 2011, 3:2374-2395.
• [39]Bessoff K, Delorey M, Sun W, Hunsperger E: Comparison of Two commercially available dengue virus (DENV) NS1 capture enzyme-linked immunosorbent assays using a single clinical sample for diagnosis of acute DENV infection. Clin Vaccine Immunol 2008, 15(10):1513-1518.
• [40]Dussart P, Labeau B, Lagathu G, Louis P, Nunes MRT, Rodrigues SG, Storck-Herrmann C, Cesaire R, Morvan J, Flamand M: Evaluation of an enzyme immunoassay for detection of dengue virus NS1 antigen in human serum. Clin Vaccine Immunol 2006, 13(11):1185-1189.
• [41]Guzman MG, Jaenisch T, Gaczkowski R, Hang VTT, Sekaran SD, Kroeger A, Vazquez S, Ruiz D, Martinez E, Mercado JC: Multi-country evaluation of the sensitivity and specificity of two commercially-available NS1 ELISA assays for dengue diagnosis. PLoS Negl Trop Dis 2010, 4(8):e811.
• [42]Roehrig JT, Hombach J, Barrett AD: Guidelines for plaque-reduction neutralization testing of human antibodies to dengue viruses. Viral Immunol 2008, 21(2):123-132.